

PRIOR AUTHORIZATION REQUEST FORM
PANCREATIC ENZYMES

Creon®, Viokace®, Pancreaze®, Pertzze®, Zenpep®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: Creon® (pancrelipase), Zenpep® (pancrelipase)

Non-preferred: Viokace® (pancrelipase), Pancreaze® (pancrelipase), Pertzze® (pancrelipase)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have exocrine pancreatic insufficiency caused by cystic fibrosis (CF)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does the member have exocrine pancreatic insufficiency due to pancreatectomy (including Whipple procedure)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does the member have exocrine pancreatic insufficiency due to chronic pancreatitis or other conditions (including type 1 diabetes mellitus) and one of the following: <ul style="list-style-type: none"> Fecal elastase-1 <200mcg Fecal elastase-1 <250mcg/g on two distinct tests Peak bicarbonate concentration <80mEq/L (from a direct pancreas function testing with an endoscopic secretin test (one-hour method) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. If the member has pancreatic insufficiency due to excessive alcohol consumption, has the following been documented: <ul style="list-style-type: none"> Alcohol cessation counseling Offer to enroll in an alcohol abuse program 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

3. Has the therapy shown to be effective with an improvement in condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member show a continued need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 080
 Origination Date: 09/04/2019
 Reviewed/Revised Date: 12/22/2020
 Next Review Date: 12/22/2021
 Current Effective Date: 01/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.